Tampilkan postingan dengan label pharmaceutical. Tampilkan semua postingan
Tampilkan postingan dengan label pharmaceutical. Tampilkan semua postingan

Selasa, 12 September 2017

Developing a new drug does NOT cost $2.7 billion

Today's Managing Health Care Costs Number is $648 million


Source  Dark bars are R&D costs, while lighter bars are revenue.   One of 9 medications has not yet paid back its R&D costs 

JAMA Internal Medicine published an analysis of the cost of bringing a new cancer drug to market yesterday - and the cost is only 1/3 of what researchers at Tufts had previously estimated.  The researchers used SEC filings for 10 small companies which had no drugs on the market in 2007 - and divided the reported research and development costs of each company by the number of approved drugs to estimate total R&D cost.   The median estimated R&D cost was $648 million.

The  payoffs for these companies was enormous.  Total estimated R&D costs were $7.2 billion ($9.2 billion with discounting), and revenue for these drugs was $67 billion - and that revenue will continue for years to come.

This methodology to estimate research and development costs is not perfect.   It could substantially underestimate the cost to the extent that the researchers are only including companies that succeeded.    Many potential oncology drugs fail - and thus the researchers would not have been poring through their company's SEC 401K filings.  Further, companies expend resources on activities other than research to bring a drug to market.  On the other hand, the analysis doesn’t account for tax benefits for R&D -  which lower the cost substantially.

Most of the cost of developing new drugs is not due to regulations - and is especially not due to "excess regulation".  Half of these new medications were approved through the FDA's expedited process.  These drugs are indicated for small populations, so the FDA accepted studies that were small for their approval.

The New York Times has an article on its current electronic front page asserting that the $475, 000 cost of Kymriah will be the norm for gene therapy.  The article notes that there are 34 gene therapy drugs in the pipeline, and 470 in initial clinical trials. 

This research on the cost of new drug development helps show that such high prices are not "necessary" to support research and development.  But the pharmaceutical companies will continue to charge these high prices as long as they are able to.  We clearly need ceiling prices, barriers to approval based on initial price, or system-wide price negotiations if we don't want to see pharmaceutical costs continue to drive lack of health care affordability.


Jumat, 01 September 2017

$475,000 is a good deal for Kymriah, and a bad sign for controlling health care costs

$475,000 is a good deal for Kymriah, and a bad sign for controlling health care costs

Today's Managing Health Care Costs Number is $475,000

Personalized medicine is here - and it's a miracle.  Novartis' newly-approved drug Kymriah is genetically engineered immune cells from the patient which will kill leukemia cells, and it's shown remarkable efficacy in small trials.  One girl was dying of leukemia five years ago and remains in remission, and gave stirring testimony for the drug's approval before the FDA last month. (Photo of Emily Whitehead, above, is from the Associated Press via the NY Times)

This is just the beginning - training one's own immune cells to fight cancer (and possibly other diseases) holds enormous promise.  The cost: $475,000 for the one-time treatment.

Here are the reasons we shouldn't worry about that eye-popping cost

  • $475,000 is a small price to pay for a cure of an otherwise fatal disease- especially in a kid.  With a life expectancy of 70 years, this could mean the cost per Quality Adjusted  Life Year (QALY) is under $7000.
  • The drug has been approved for a rare cancer- with under 60 people likely to be eligible each year.  If all of them responded and paid full price, that's under $30 million.   Putting this in perspective, this is 0.0008% of national health care expenditures.
  • Novartis will restrict use to just 30-35 centers, so we won't have unqualified physicians prescribing this willy-nillly.  The engineered cells can cause life-threatening reactions - so this is an important safety measure
  • Novartis has promised refunds if there is no response in 1 month, and has also promised financial assistance for families without insurance coverage

You can probably guess that I'm worried, though.

Kymriah is the first of a set of CAR-T therapies - and there are a gaggle more on the way.  Some of them will be used for much more common conditions, and even Kymriah is likely to be used much more widely than the FDA-approved indications.   Gilead Pharmaceuticals just paid $11 billion for Kite, a cancer therapy company that has a CAR-T therapy tailored to non-Hodgkins Lymphoma expected to be approved in the next year.  The cost is likely to be similar, and the market larger. The total cost for CAR-T therapies will likely rise to many billions in just a few years.

Novartis has broken yet another price ceiling -and this will make it easier for the prices of other oncology medicines to continue to rise.   See this post for how this works with Multiple Sclerosis drugs.

Refunds for non-efficacy sound good in theory - but are often ineffective in practice.  This research showed "such schemes have poorly contributed to the fulfillment of the purpose in Italy, producing a trifling refund."

Financial assistance programs have largely been focused on maintaining price discipline - and have helped contribute to pharmaceutical company bottom lines by increasing revenue from other payers and offering the pharmas favorable tax treatment.

These genetically engineered cells will never be produced by a generic company - and are unlikely even to be produced as biosimilars for a long time if ever.   So if very high prices "stick," we should expect to pay them for the foreseeable future.

We should celebrate - this is an enormous feat of American medicine.  The initial research was performed at the University of Pennsylvania - but this drug would never had made it to market without the investment, trials, and regulatory work done by Novartis.

But we need to address drug prices if we are to control health care costs, and the high price set for Kymriah  is a bad omen.

Rabu, 29 Maret 2017

New EpiPen alternative for $4500!


Today’s Managing Health Care Costs Number is $4500



It seems like eons ago that we were arguing over EpiPen – an autoinjector that delivers a dirt-cheap generic medication that can save the life of someone who has an allergic reaction.  The drug was purchased by Mylan pharmaceuticals which progressively raised its price from $100 to $750 – and faced massive public outcry. 

Mylan’s CEO (the daughter of WV Senator Joe Manchin (D)) was subjected to Congressional hearings, and the company lowered the price (from $750 to $600) and introduced a generic version for half the price (which undersold another generic)

One interesting sidenote was that there had been an EpiPen competitor, Auvi-Q, produced by Sanofi, which gave audio instructions for injection. This had been priced competitivelywith EpiPen when it was introduced in 2013 (each was a bit shy of $250 for two doses) - but had been removed from the market due to production issues.

Good news.  Auvi-Q is back!

Not so good news.  Auvi-Q is priced at $4500 for two doses.

WHAT? 

It’s getting hard to summon outrage about pharmaceutical prices (and a lot else).  Why should a delivery system that was priced at $250 in 2013 be marketed for $4500 in 2017?  Obviously, when it comes to pricing there is no shame – the company selling this also sells Evzio, an autoinjector for naloxone  to reverse narcotic overdose for $4500

EpiPen Google searches 


Kamis, 13 Oktober 2016

   Drug coupons increase medical costs

Drug coupons increase medical costs


Today's Managing Health Care Cost Number is $2.7 billion

Coupons are a marketing approach to segmenting customers.  The manufacturer using coupons is able to collect a premium price from those purchasers which are not price sensitive, but doesn’t have to sacrifice the volume from price sensitive customers who would otherwise purchase a cheaper product.  

This is true in the grocery section - brand name groceries cost more than store brands, but consumers who are price sensitive clip coupons to get a price that's at least sometimes even lower than the store brand.  But the brand name food company can continue to command high prices from those who didn't clip coupons.

This is especially true in the pharmaceutical space.  Kesselheim and colleagues estimated that pharma coupons increase total medical costs by about $2.5 billion in the US in 2013.   In today's New England Journal, researchers note that fully half the revenue from name brand noninjectable medications comes from drugs for which manufacturers offer coupons.   This generally raises acquisition costs by 60% - as the coupon decreases member out of pocket spend, but does not decrease insurance company spend.

In recent years, the number of copayment coupons being offered has skyrocketed. We estimate that in 2007, a quarter of noninjectable, brand-name drug revenue derived from drugs with copayment coupons; by 2010, that proportion had more than doubled. The availability of coupons has since become rampant; they now appear even in mainstream magazines. We recently examined how these coupons affect spending for drugs that are facing new competition from a generic bioequivalent.3 We estimate that coupons increase the percentage of prescriptions filled with brand-name formulations by more than 60%. Back-of-the-envelope calculations suggest that, on average, each copayment coupon increased national spending on all drugs by $30 million to $120 million over the 5-year period following generic entry. In our sample, consisting of 85 drugs facing generic competition for the first time between 2007 and 2010, we estimate that spending on the 23 drugs with coupons was $700 million to $2.7 billion higher than it would have been if the coupons had not been issued or had been banned.

Today's article notes that these coupons undermine "value based contracting," and that Medicare, Medicaid, and Massachusetts prohibit drug coupons.  (The article is incorrect; Massachusetts lifted the ban on drug coupons in 2012 after substantial pharmaceutical company lobbying). They also note that high priced providers could use similar approaches to retain volume while continuing to charge above-market rates.

Related posts on this topic:




Rabu, 21 September 2016

Pharma spent $880 million lobbying to prevent opioid regulations over 10 years

Pharma spent $880 million lobbying to prevent opioid regulations over 10 years

Today's Managing Health Care Costs Number is $880 million


The Associated Press and the Center for Public Integrityreported on pharmaceutical company lobbying at the state level earlier this week;  this was to look specifically at lobbying around opiod regulation.  Pharma spent $880 million over a decade - while the anti-opioid lobby spent about $4 million.   The industry and allied groups have an "army of lobbyists averaging 1,350 per year covering all 50 state capitals."  The report says that the opioid lobby spent eight times as much as the gun lobby for political activities over the last decade.

This matters. While the attention of the national press is on Congress and the Food and Drug Administration, most laws around prescription practice are enacted on the state level. The level of scrutiny for state governmental action is low.  Few Americans know who their state legislators are -never mind whether they have voted for bills that promote excessive use of dangerous, addictive medications.   One percent of local news coverage is about the state legislature.

Many state legislatures pass bills that are written by lobbyists, and pharmaceutical companies have funded "astroturf" groups like the Pain Care Forum to promote their interests, and there is even a division of the American Cancer Society (the Cancer Action Network) which has lobbied against opioid legislation in 18 states.  States determine what rules pharmacies and prescribing clinicians must follow - and as of earlier this year only 16 states had mandatory prescription drug monitoring databases for physicians to use to prevent doctor shopping for narcotics.

We need more attention to state legislative and regulatory processes -and this reporting is a good start.  Pharma doesn't always win - the AP report includes a sidebaron a pharma company failure to stop opioid regulations in Washington State.